公开(公告)号：WO2008082537A2

公开(公告)日：2008-07-10

申请号：PCT/US2007/025878

申请日：2007-12-18

Applicant: PARTNERS HEALTHCARE RESEARCH VENTURES & LICENSING ,  GUPTA, Vineet ,  AMIN, Arnaout, M.

Inventor： GUPTA, Vineet ,  AMIN, Arnaout, M.

IPC: A61K31/427

CPC classification number: G01N33/5032 ,  C07C233/81 ,  C07C251/20 ,  C07C311/39 ,  C07C2601/14 ,  C07D213/85 ,  C07D239/48 ,  C07D249/10 ,  C07D263/46 ,  C07D265/34 ,  C07D277/14 ,  C07D277/36 ,  C07D277/42 ,  C07D277/54 ,  C07D277/72 ,  C07D311/16 ,  C07D333/22 ,  C07D333/68 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/06 ,  C07D498/04 ,  C07D513/18

Abstract: The application describes an assay for the identification of small molecule modulators of integrin CDl lb/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

Abstract translation: 本申请描述了用于鉴定整联蛋白CD11b / CD18的小分子调节剂和能够调节该受体活性的小分子的测定法。 此类化合物可用于某些实施方案中用于治疗选自炎症，免疫相关病症，癌症，局部缺血 - 再灌注损伤，中风，与血管损伤相关的新内膜增厚，大疱性类天疱疮，新生儿梗阻性肾病和心血管疾病的疾病或病症， 或在其他实施方案中用于治疗选自免疫缺陷，获得性免疫缺陷综合征（AIDS），髓过氧化物酶缺乏症，Wiskott-Aldrich综合征，慢性肉芽肿病，高IgM综合征，白细胞粘附缺陷症，Chediak-Higashi综合征 ，以及严重的联合免疫缺陷。

公开(公告)号：WO2008082537A3

公开(公告)日：2008-08-28

申请号：PCT/US2007025878

申请日：2007-12-18

Applicant: PARTNERS HEALTHCARE RES VENTUR ,  GUPTA VINEET ,  AMIN ARNAOUT M

Inventor： GUPTA VINEET ,  AMIN ARNAOUT M

IPC: A61K31/397

CPC classification number: G01N33/5032 ,  C07C233/81 ,  C07C251/20 ,  C07C311/39 ,  C07C2601/14 ,  C07D213/85 ,  C07D239/48 ,  C07D249/10 ,  C07D263/46 ,  C07D265/34 ,  C07D277/14 ,  C07D277/36 ,  C07D277/42 ,  C07D277/54 ,  C07D277/72 ,  C07D311/16 ,  C07D333/22 ,  C07D333/68 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/06 ,  C07D498/04 ,  C07D513/18

Abstract: The application describes an assay for the identification of small molecule modulators of integrin CDl lb/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.

Abstract translation: 该申请描述了用于鉴定整合素CD11b / CD18的小分子调节剂和能够调节该受体活性的小分子的测定法。 这些化合物可用于某些实施方案中用于治疗选自炎症，免疫相关疾病，癌症，缺血再灌注损伤，中风，与血管损伤相关的新内膜增厚，大疱性类天疱疮，新生儿梗阻性肾病和心血管疾病的疾病或病症， 或在其它实施方案中用于治疗选自免疫缺陷，获得性免疫缺陷综合征（AIDS），髓过氧化物酶缺乏症，威斯科特 - 奥德里奇综合征，慢性肉芽肿病，超IgM综合征，白细胞粘附缺陷，Chediak-Higashi综合征 ，和严重的联合免疫缺陷。

公开(公告)号：WO2019118646A1

公开(公告)日：2019-06-20

申请号：PCT/US2018/065288

申请日：2018-12-12

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  THE GENERAL HOSPITAL CORPORATION ,  PARTNERS HEALTHCARE

Inventor： PAHLEVANINEZHAD, Hamid ,  KHORASANINEJAD, Mohammadreza ,  HUANG, Yao-Wei ,  SHI, Zhujun ,  SUTER, Melissa ,  CAPASSO, Federico

IPC: A61B1/00 ,  A61B5/00 ,  G02B23/24 ,  G02B1/00

Abstract: An endoscopic imaging device (e.g., a catheter) comprises a light-transmitting tubing, at least one optical fiber disposed in the light-transmitting tubing, and at least one metalens. The metalens is optically coupled to the optical fiber and is configured to focus light from the optical fiber, through the light-transmitting tubing, and to a target point located outside of the light-transmitting tubing. The metalens includes a plurality of nanostructures. The nanostructures define a phase profile that corrects astigmatism caused by the light- transmitting tubing.